Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Herb Greenberg, 'Herb on the Street' author, joins 'Power Lunch' to discuss Greenberg's thoughts on the terminated ...

Hims & Hers fell by 34.63 percent on Monday to close at $41.98 apiece after Novo Nordisk terminated its marketing partnership ...

Live Updates Live Coverage Has Ended Bullish on Meta 12:09 pm by Gerelyn Terzo Analysts at Wall Street firm Citigroup are ...

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...

The Novo Nordisk partnership ending does not alter my long-term bullish thesis on HIMS; the company is much more than just a ...

Hims & Hers Health, a telehealth company, offers direct-to-patient platform to distribute prescription drugs and OTC ...

It’s not often that investors come across the kind of companies that can yield a multi-bagger investment over the years.

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

Stock markets have rallied and oil prices fell after U.S. President Donald Trump announced what appears to be a shaky ...

It's common to get stuck on the latest headlines and fixate on what they mean for your portfolio. But regardless of what parts of the stock market rise and fall based on the latest news out ...